「20」の検索結果

Performs subgroup and heterogeneous treatment effect (HTE) analyses for clinical trials. Covers Mantel-Haenszel pooling, Breslow-Day, interaction tests in regression, RERI for additive interaction, modern data-adaptive HTE methods (STEPP, SIDES, causal forests, X/R-learners), Bayesian shrinkage (Dixon-Simon, MAP, EXNEX), graphical multiplicity (Bretz-Maurer), and credibility frameworks (Sun BMJ, EMA 2019). Use when analyzing treatment effects across patient subgroups for regulatory submissions or precision-medicine claims.

日本語の概要は準備中です。原文の説明を表示しています。

Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Estimate SNP heritability and partition it across functional annotations, cell types, and loci from GWAS summary statistics or individual-level genotypes. Implements LDSC, stratified LDSC with the baseline-LD model, Finucane 2018 cell-type prioritization, LDAK SumHer, HDL, HESS local heritability, BOLT-REML, GCTA-GREML, graphREML, and Popcorn cross-population genetic correlation. Use when computing total h2_SNP from summary stats, partitioning heritability across functional categories, prioritizing trait-relevant tissues or cell types from ENCODE/Roadmap chromatin marks, reconciling LDSC vs LDAK enrichment estimates, computing local heritability with HESS, estimating genetic correlation between traits, or producing publication-grade enrichment with calibrated sensitivity to model assumptions.

日本語の概要は準備中です。原文の説明を表示しています。

Fits structural equation models to GWAS summary statistics using GenomicSEM (Grotzinger 2019), including common-factor models, confirmatory factor models, ESEM, common-factor GWAS with Q_SNP heterogeneity, multivariate Wald tests, and stratified GenomicSEM partitioned heritability. Reconciles results against MTAG multi-trait analysis. Handles sample overlap via the LDSC sampling-covariance matrix, identifies and resolves Heywood cases, and verifies model fit with CFI / RMSEA. Use when modeling latent genetic architecture across correlated traits, running multivariate GWAS on a shared factor, distinguishing factor-mediated from trait-specific SNP effects, or comparing GenomicSEM common-factor results against MTAG when both depend on accurate sampling covariance.

日本語の概要は準備中です。原文の説明を表示しています。

Identifies super-enhancers from H3K27ac, MED1, or BRD4 ChIP-seq using ROSE, ROSE2, LILY, HOMER -style super, and ENCODE dELS cross-referencing. Handles peak stitching parameters, ranking choices, hockey-stick inflection, marker choice (H3K27ac vs MED1/BRD4), and cross-condition comparison with spike-in normalization. Constructs core regulatory circuitry (Saint-Andre 2016) from SE-encoded TFs. Use when identifying cell-identity / cancer-associated regulatory domains, comparing super-enhancers between conditions, identifying master transcription factor networks, or predicting BET-inhibitor responsiveness.

日本語の概要は準備中です。原文の説明を表示しています。

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Reads, writes, and converts molecular file formats (SMILES, InChI, SDF V2000/V3000, MOL2, PDB, MMTF) using RDKit and Open Babel with rigorous handling of aromaticity perception, stereochemistry, implicit/explicit hydrogens, kekulization, and salt/fragment separation. Use when loading chemical libraries, debugging parse failures, or preparing molecules for downstream standardization, descriptor calculation, or docking.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes alternative splicing from PacBio Iso-Seq (HiFi, Kinnex/MAS-Iso-seq) and Oxford Nanopore (direct cDNA, direct RNA, R10.4.1+) long-read RNA-seq with full-isoform resolution. Tools include FLAIR (correct/collapse/quantify/diffSplice for PacBio + ONT), IsoQuant (de-novo or annotation-guided isoform discovery 2024 SOTA), Bambu (annotation-aware Bayesian discovery + quantification with Novel Discovery Rate), SQANTI3/SQANTI-LR (isoform classification: FSM/ISM/NIC/NNC + artifact flags), rMATS-long (event calling on long-read isoforms), and minimap2 (-ax splice:hq for HiFi; -ax splice -k14 for ONT cDNA; add -uf only for direct RNA or stranded cDNA preps). Solves microexon detection, recursive splicing, complex multi-exon isoforms, and DTU without transcript-quantification uncertainty. Use when short-read AS limitations (anchor length, complex isoforms, microexons, recursive splicing, transcript ambiguity) demand full-isoform resolution.

日本語の概要は準備中です。原文の説明を表示しています。

Build a differential-ready consensus peakset from per-replicate ATAC-seq peaks using iterative overlap removal, fixed-width re-centering, and majority-rule overlap. Use when generating a stable peak coordinate system for downstream differential accessibility, ML feature engineering, cross-sample comparison, or fixed-width peak counts; covers Corces 2018 iterative overlap (501 bp), DiffBind summit re-centering, and ENCODE consistency rules.

日本語の概要は準備中です。原文の説明を表示しています。

Predicts whether a DNA variant alters mRNA splicing using sequence-based deep-learning tools — SpliceAI (10kb context dilated CNN, clinical default), Pangolin (multi-tissue), MMSplice (modular per-region CNN with calibrated ΔPSI), SpliceTransformer/TrASPr (tissue-aware transformers), SpliceVault (empirical 300K-RNA lookup of likely mis-splicing outcomes), CADD-Splice (composite score). Applies the ClinGen SVI 2023 framework for ACMG/AMP variant interpretation (PVS1, PP3, BP4 evidence codes), HGVS splicing nomenclature (c.123+1G>A, c.123-3T>G, r.spl?), extended-window scoring for deep-intronic pseudoexons, tissue-specific predictions, branchpoint variant detection (BPHunter, LaBranchoR), and splice-switching ASO design. Use when interpreting splice impact of clinical variants, prioritizing VUS, identifying deep-intronic pathogenic variants, or designing ASOs.

日本語の概要は準備中です。原文の説明を表示しています。

Quantifies alternative splicing as PSI (percent spliced in) from RNA-seq using rMATS-turbo (BAM-based event), SUPPA2 (TPM-based event), MAJIQ V3 (LSV-based Bayesian), leafcutter (annotation-free intron clusters), VAST-TOOLS (cross-species with microexon support), Shiba (junction-imbalance-corrected, 2025 SOTA at low coverage), or IRFinder-S (intron retention coverage-aware). Distinguishes the five canonical event classes (SE, A5SS, A3SS, MXE, RI), special classes (microexons, exitrons, AFE/ALE), intron retention subtypes (canonical RI vs detained introns), and applies effective-length normalization. Use when measuring splice-site usage or isoform inclusion ratios from short-read RNA-seq.

日本語の概要は準備中です。原文の説明を表示しています。

Detects differential alternative splicing between conditions using rMATS-turbo (binomial LRT on junction counts), leafcutter (Dirichlet-multinomial GLM on intron clusters), MAJIQ V3 deltapsi/HET (Bayesian posterior on LSVs), SUPPA2 (empirical-null on TPM-derived PSI), or Shiba (junction-imbalance-corrected, 2025 SOTA at low coverage). Reports FDR-corrected significance and delta PSI effect sizes. Tools differ in statistical model, annotation dependence, calibration regime, and replicate-count requirements. Use when comparing splicing patterns between treatment groups, tissues, or disease states.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about carrier-driver relationships — Independent Contractor (IC / 1099) vs Employee (W-2), Owner-Operator lease agreements, the AB5 California law, the DOL 2024 IC test, lease-purchase programs from the carrier side, settlement statements, deductions, and how to structure a compliant IC arrangement. Cite 49 CFR 376 + 1099 IRS rules.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill to track recent and upcoming SMS methodology changes from FMCSA. Covers proposed rule changes, comment periods, and implementation timelines.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks how to design or improve a fleet safety scorecard — what KPIs to track, how to weight them, telematics signals vs document compliance vs roadside outcomes, monthly cadence, driver-facing vs admin-facing dashboards, gamification considerations, peer-comparison metrics, and how a scorecard ties to insurance premiums + retention. Reference SMS Methodology v3.20 for industry-standard weights.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about FMCSA Compliance Safety Accountability (CSA) program scoring — the seven BASIC categories, BASIC Severity Indicator (BSI), peer percentiles, intervention thresholds, how violations age out, SMS Methodology, ISS (Inspection Selection System), what "alert" status means, Safety Measurement System mechanics, or DataQ disputes. Cite SMS Methodology v3.20.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill for transporting steel coils. Covers § 393.120 specific rules, chain requirements, dunnage placement, and inspection procedures.

日本語の概要は準備中です。原文の説明を表示しています。

The one association system (platform.associations) and schema-qualified table refs. Use when touching an M2M junction table, an associate_*/attach_*/tag_* RPC, FK columns used as tags, a 'things attached to X' list or card, or a PGRST205 / 42703 table-not-found on a bare .from().

日本語の概要は準備中です。原文の説明を表示しています。

プロジェクト全体（または指定範囲）を最も美しい確定版へ仕上げる．範囲を媒体に分解して refine プラグインの各スキルへ委譲し，媒体間の継ぎ目を走査する．「プロジェクト全体を完璧にして」「全部洗練して」など，媒体をまたぐ仕上げを求められたときに使う．単一媒体の仕上げは refine プラグインの該当スキルを使う．

課題のレポート・小論文部分を，出題文・採点基準の要求を過不足なく満たす形で執筆する．「レポートを書いて」「この設問に答えて」など，課題文書の執筆を求められたときに使う（既存文書の推敲だけなら /refine:docs を使う）．

リリース単位（単一パッケージか monorepo か）を判定し，SemVer でバージョンを上げ（マニフェストと全参照箇所を整合），bump コミット・タグ・push・About 欄・GitHub Release までの文面を提案．承認後に一気に実行する．「リリースして」「公開して」「バージョンを上げて」など版を公にすることを求められたときに使う．記録するだけなら /capstone:commit を使う．

実行中・実行済みのプログラムやジョブの状況を知りたいとき，自分が起動したものか無関係のものかを問わず調べて答える．「どうなってる？」「学習状況は？」「進捗見せて」など，実行そのものを頼んでいるわけではなく既存の何かの様子を尋ねられたときに使う．新しく実行を頼まれたときは /ops:exec を使う．

参照文書（README・SKILL.md・API 文書・Markdown 全般）を美の基準で走査し，最も美しい確定版へ仕上げる．「READMEを完璧にして」「ドキュメントを美しくして」など，文書の仕上げを求められたときに使う（単発の小修正には使わない）．

コード（スクリプト・設定含む）を美の基準で走査し，公開挙動を保ったまま最も美しい確定版へ仕上げる．「コードを完璧にして」「リファクタして美しく」「コードを洗練して」など，コードの仕上げを求められたときに使う（単発の小修正には使わない）．